SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: bw who wrote (1357)7/20/1999 8:01:00 AM
From: vestor  Read Replies (2) of 1837
 
August numbers, I believe, will not be great because of ramp-up costs for Cenestin and the other recent approvals. I believe the company had said just that. It takes time to get a new drug accepted. Many have prescriptions that are a supply for a considerable length of time. Some get automatic renewals until they have a periodic check-up and then alternative medicines may be discussed. It just takes time. My wife is still on her last prescription of Premarin but will definitely approach the matter of Cenestin as soon as that supply runs out. I think we need to give DRMD time and the drug time to get accepted. In the meantime DRMD is moving along with the bone studies needed for long term usage and also their combinative NDA's. I would like to see DRMD increase public exposure with some emphasis on where Premarin comes from, its lack of uniformity and how the source (horses) live that produce Premarin. This can done and still take the high road.

The last word from DRMD is that sales are proceeding as previously estimated and earlier than estimated. The fact that there are no earnings estimates gives us no benchmark to measure against. However, I recently saw a newsletter come out recommending DRMD citing Cenestin and the 'womens health' direction the company is taking.

Patience..... P.S. - Thanks for waking me up.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News